March 20, 2020 / 9:04 PM / 14 days ago

BRIEF-FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes

March 20 (Reuters) - Eli Lilly and Co:

* US FDA ISSUES COMPLETE RESPONSE LETTER FOR EMPAGLIFLOZIN 2.5 MG AS ADJUNCT TO INSULIN FOR ADULTS WITH TYPE 1 DIABETES

* ELI LILLY AND - LETTER INDICATES FDA IS UNABLE TO APPROVE APPLICATION IN CURRENT FORM

* ELI LILLY AND CO - EMPAGLIFLOZIN 2.5 MG IS BEING DEVELOPED BY BOEHRINGER INGELHEIM & ELI LILLY AND COMPANY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below